Premium
The potential danger of empiric antimicrobial therapy for nosocomial SBP
Author(s) -
O'Brien Alastair,
China Louise,
Gant Vanya
Publication year - 2016
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.28733
Subject(s) - antibiotics , medicine , antibiotic resistance , intensive care medicine , empiric therapy , antimicrobial , cephalosporin , carbapenem , microbiology and biotechnology , biology
tively impacted NASH resolution. In contrast, data from the LEAN trial indicated that histological improvements were not proportional to extent of WL and that the presence of diabetes did not affect NASH resolution rates. These findings probably should explain the low accuracy of the model in detecting patients with NASH resolution. In terms of NASH resolution, the patient’s response to therapeutic interventions depends partly on the patient’s characteristics and the histologic severity of NASH. Patients with unfavorable prognostic factors (i.e., older age, diabetes, or nonalcoholic fatty liver disease activity score 5) and lack of efficacy of the intervention suspected by surrogate markers (i.e., absence of ALT normalization or lower rates of WL) may have lower probabilities of NASH resolution. In the presence of the above-mentioned scenarios, the model should consistently identify patients without NASH resolution.